Minerva Neurosciences CEO Rémy Luthringer Presents Roluperidone for Negative Symptoms of Schizophrenia

Minerva Neurosciences presented roluperidone, its lead candidate for negative symptoms of schizophrenia, on a conference call held November 12, 2026. Executive Chairman and CEO Rémy Luthringer led the presentation, Seeking Alpha reported. Minerva Neurosciences is a clinical-stage biopharmaceutical company developing central nervous system therapies, with roluperidone in Phase 3 trials for negative symptoms of schizophrenia.

Luthringer Frames Roluperidone as Long-Sought Option

Luthringer opened the call by describing the decades of effort behind the condition. "As you know, since 70 years, people have tried hard in order to improve negative symptoms of patients suffering with schizophrenia," he said. He added that roluperidone is "really, really creating some hope for patients."

Luthringer told attendees the session would cover where the program stands and where it is going. He noted that Minerva is a public company and directed listeners to its SEC filings for more information. He introduced Dr. Gregory Strauss as one of three people he described as extremely important for the space, saying the two have worked together for a long time.

Minerva's Advisory Board and Phase 3 Trial

According to akta.pro company records, Minerva established a Scientific Advisory Board in June 2026 with academic key opinion leaders in schizophrenia and CNS drug development to support regulatory interactions and clinical execution. In March 2026 the company initiated the confirmatory Phase 3 trial of roluperidone in approximately 380 patients with negative symptoms of schizophrenia across U.S. and European sites.

The same records show Minerva appointed Jim O'Connor as Chief Business Officer and General Counsel in April 2026, a move described as signaling a transition from purely clinical operations to commercial readiness. Minerva was founded in 2014 and is headquartered in Waltham, with a headcount range of 1-10 and a revenue estimate of pre-revenue.

Earlier Steps Toward the Roluperidone Program

Minerva announced on August 28, 2026 that management would participate in two investor conferences in New York, Stock Titan reported. The company said on May 18, 2026 that Luthringer would take part in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 4:20 PM ET in New York, GlobeNewswire reported.

MarketBeat reported that Minerva was set to announce third-quarter 2026 earnings on October 28, 2026, with analysts expecting a loss of $0.14 per share.

What Comes Next for Minerva

The confirmatory Phase 3 trial of roluperidone is underway across U.S. and European sites, and the Scientific Advisory Board formed in June 2026 is intended to support regulatory interactions.